Literature DB >> 16195375

Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero.

Annalisa Frattini1, Harry C Blair, Maria Grazia Sacco, Francesco Cerisoli, Francesca Faggioli, Enrica Mira Catò, Alessandra Pangrazio, Antonio Musio, Francesca Rucci, Cristina Sobacchi, Allison C Sharrow, Sara E Kalla, Maria Grazia Bruzzone, Roberto Colombo, Maria Cristina Magli, Paolo Vezzoni, Anna Villa.   

Abstract

Autosomal recessive osteopetrosis (ARO) is a paradigm for genetic diseases that cause severe, often irreversible, defects before birth. In ARO, osteoclasts cannot remove mineralized cartilage, bone marrow is severely reduced, and bone cannot be remodeled for growth. More than 50% of the patients show defects in the osteoclastic vacuolar-proton-pump subunit, ATP6a3. We treated ATP6a3-deficient mice by in utero heterologous hematopoietic stem cell (HSC) transplant from outbred GFP transgenic mice. Dramatic phenotype rescue by GFP osteoclasts was obtained with engraftment, which was observed in most cases. Engraftment survived for variable periods. Recipients were not immunosuppressed, and graft-versus-host disease was not observed in all pups born after in utero treatment. Thus, differentiation of unmatched HSC transplanted in utero is sufficient to prevent fatal defects in ARO and may prevent complications of ARO unresponsive to conventional bone marrow transplantation. The presence of defective cells is not a barrier to the rescue of the phenotype by donor HSC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195375      PMCID: PMC1253616          DOI: 10.1073/pnas.0507637102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  Mixed chimerism and transplant tolerance.

Authors:  M Sykes
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

2.  High-level allogeneic chimerism achieved by prenatal tolerance induction and postnatal nonmyeloablative bone marrow transplantation.

Authors:  William H Peranteau; Satoshi Hayashi; Michael Hsieh; Aimen F Shaaban; Alan W Flake
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

3.  Osteoclastic bone resorption by a polarized vacuolar proton pump.

Authors:  H C Blair; S L Teitelbaum; R Ghiselli; S Gluck
Journal:  Science       Date:  1989-08-25       Impact factor: 47.728

4.  Transplanted bone marrow regenerates liver by cell fusion.

Authors:  George Vassilopoulos; Pei-Rong Wang; David W Russell
Journal:  Nature       Date:  2003-03-30       Impact factor: 49.962

5.  HLA-haploidentical blood progenitor cell transplantation in osteopetrosis.

Authors:  Ansgar S Schulz; Carl Friedrich Classen; Walther A Mihatsch; Michael Sigl-Kraetzig; Markus Wiesneth; Klaus-Michael Debatin; Wilhelm Friedrich; Susanna M Müller
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

6.  B cell function after haploidentical in utero bone marrow transplantation in a patient with severe combined immunodeficiency.

Authors:  J Bartolomé; F Porta; A Lafranchi; J J Rodríguez-Molina; E Cela; A Cantalejo; E Fernández-Cruz; A Gómez-Pineda; A G Ugazio; L D Notarangelo; J Gil
Journal:  Bone Marrow Transplant       Date:  2002-04       Impact factor: 5.483

7.  Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion.

Authors:  Satoshi Hayashi; William H Peranteau; Aimen F Shaaban; Alan W Flake
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

8.  Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report.

Authors:  G J A Driessen; E J A Gerritsen; A Fischer; A Fasth; W C J Hop; P Veys; F Porta; A Cant; C G Steward; J M Vossen; D Uckan; W Friedrich
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

9.  Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis.

Authors:  Annalisa Frattini; Alessandra Pangrazio; Lucia Susani; Cristina Sobacchi; Massimiliano Mirolo; Mario Abinun; Marino Andolina; Adrienne Flanagan; Edwin M Horwitz; Ercan Mihci; Luigi D Notarangelo; Ugo Ramenghi; Anna Teti; Johan Van Hove; Dragana Vujic; Terri Young; Alberto Albertini; Paul J Orchard; Paolo Vezzoni; Anna Villa
Journal:  J Bone Miner Res       Date:  2003-10       Impact factor: 6.741

10.  Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis.

Authors:  Anna Taranta; Silvia Migliaccio; Irene Recchia; Maurizio Caniglia; Matteo Luciani; Giulio De Rossi; Carlo Dionisi-Vici; Rita M Pinto; Paola Francalanci; Renata Boldrini; Edoardo Lanino; Giorgio Dini; Giuseppe Morreale; Stuart H Ralston; Anna Villa; Paolo Vezzoni; Domenico Del Principe; Flaminia Cassiani; Giuseppe Palumbo; Anna Teti
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

View more
  19 in total

1.  Osteoclast activity modulates B-cell development in the bone marrow.

Authors:  Anna Mansour; Adrienne Anginot; Stéphane J C Mancini; Claudine Schiff; Georges F Carle; Abdelilah Wakkach; Claudine Blin-Wakkach
Journal:  Cell Res       Date:  2011-02-15       Impact factor: 25.617

2.  Fetal liver cells transplanted in utero rescue the osteopetrotic phenotype in the oc/oc mouse.

Authors:  Barbara Tondelli; Harry C Blair; Matteo Guerrini; Kenneth D Patrene; Barbara Cassani; Paolo Vezzoni; Franco Lucchini
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

Review 3.  Osteopetrosis.

Authors:  Zornitza Stark; Ravi Savarirayan
Journal:  Orphanet J Rare Dis       Date:  2009-02-20       Impact factor: 4.123

Review 4.  Osteopetrosis: genetics, treatment and new insights into osteoclast function.

Authors:  Cristina Sobacchi; Ansgar Schulz; Fraser P Coxon; Anna Villa; Miep H Helfrich
Journal:  Nat Rev Endocrinol       Date:  2013-07-23       Impact factor: 43.330

5.  In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta.

Authors:  Cristina Panaroni; Roberta Gioia; Anna Lupi; Roberta Besio; Steven A Goldstein; Jaclynn Kreider; Sergey Leikin; Juan Carlos Vera; Edward L Mertz; Egon Perilli; Fabio Baruffaldi; Isabella Villa; Aurora Farina; Marco Casasco; Giuseppe Cetta; Antonio Rossi; Annalisa Frattini; Joan C Marini; Paolo Vezzoni; Antonella Forlino
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

6.  Prognostic potential of precise molecular diagnosis of Autosomal Recessive Osteopetrosis with respect to the outcome of bone marrow transplantation.

Authors:  Anna Villa; Alessandra Pangrazio; Elena Caldana; Matteo Guerrini; Paolo Vezzoni; Annalisa Frattini; Cristina Sobacchi
Journal:  Cytotechnology       Date:  2008-09-30       Impact factor: 2.058

Review 7.  Autosomal recessive osteopetrosis: mechanisms and treatments.

Authors:  Sara Penna; Anna Villa; Valentina Capo
Journal:  Dis Model Mech       Date:  2021-05-10       Impact factor: 5.758

8.  The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer.

Authors:  Chuhan Chung; Christopher C Mader; John C Schmitz; Jorunn Atladottir; Phillip Fitchev; Mona L Cornwell; Anthony J Koleske; Susan E Crawford; Fred Gorelick
Journal:  Lab Invest       Date:  2011-02-21       Impact factor: 5.662

9.  Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow.

Authors:  Anna Mansour; Grazia Abou-Ezzi; Ewa Sitnicka; Sten Eirik W Jacobsen; Abdelilah Wakkach; Claudine Blin-Wakkach
Journal:  J Exp Med       Date:  2012-02-20       Impact factor: 14.307

10.  Developmental origin, functional maintenance and genetic rescue of osteoclasts.

Authors:  Christian E Jacome-Galarza; Gulce I Percin; James T Muller; Elvira Mass; Claudia Waskow; Frederic Geissmann; Tomi Lazarov; Jiri Eitler; Martina Rauner; Vijay K Yadav; Lucile Crozet; Mathieu Bohm; Pierre-Louis Loyher; Gerard Karsenty
Journal:  Nature       Date:  2019-04-10       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.